Last $5.13 USD
Change Today -0.16 / -3.02%
Volume 2.3M
OREX On Other Exchanges
As of 8:10 PM 07/28/14 All times are local (Market data is delayed by at least 15 minutes).

orexigen therapeutics inc (OREX) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/31/13 - $7.84
52 Week Low
11/5/13 - $4.60
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

orexigen therapeutics inc (OREX) Related Businessweek News

View More BusinessWeek News

orexigen therapeutics inc (OREX) Details

Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical product candidates for the treatment of obesity. Its product candidates include NB32, which has completed Phase III clinical trials and is being studied in a cardiovascular outcomes trial; and Empatic that has completed Phase II clinical trials. Orexigen Therapeutics, Inc. has collaboration agreement with Takeda Pharmaceutical Company Limited to develop and commercialize NB32 in the United States, Canada, and Mexico. The company was founded in 2002 and is headquartered in La Jolla, California.

50 Employees
Last Reported Date: 03/13/14
Founded in 2002

orexigen therapeutics inc (OREX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $625.0K
Acting Chief Financial Officer, Principal Acc...
Total Annual Compensation: $370.0K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $370.0K
Head of Global Contrave Program and Senior Vi...
Total Annual Compensation: $370.0K
Chief Commercial Officer
Total Annual Compensation: $296.0K
Compensation as of Fiscal Year 2013.

orexigen therapeutics inc (OREX) Key Developments

Orexigen Therapeutics, Inc. Announces Amended and Restated Bylaws

On June 27, 2014, the board of directors of Orexigen Therapeutics, Inc. determined that it was in the best interests of the company and its stockholders to amend the Amended and Restated Bylaws of the company and by resolution authorized, approved and adopted amendments to the Bylaws. The Bylaw Amendments became effective immediately upon their adoption. The Bylaw Amendments revise and enhance the advance notice provisions for stockholder proposals of business and director nominations. Specifically, the changes to the advance notice provisions include the following revisions: clarify the requirements set in Section 2.4 of the Bylaws that apply to all stockholder proposals and director nominations by stockholders and are the exclusive means for stockholders to submit such matters, other than proposals and nominations governed by Rule 14a-8 under the Securities Exchange Act of 1934, as amended (which provides certain procedural requirements); require stockholders to disclose all ownership interests in the company, including, among other things, all ownership interests, hedges, economic incentives and rights to vote any shares of any security of the company, in light of increased use by investors of derivative instruments that are not reflected in an investor's beneficial ownership of the company's securities; require stockholders nominating directors to disclose the same information about a proposed director nominee that would be required if the director nominee were submitting a proposal and any material relationships between the stockholder proponents and their affiliates, on the one hand, and the director nominees and their affiliates, on the other hand; and require that the additional disclosures discussed above be updated and supplemented, if necessary, so as to be accurate as of the record date for a meeting and as of shortly prior to the meeting.

Orexigen Therapeutics, Inc. - Special Call

To review of the resubmitted New Drug Application for NB32, the company's investigational medication being evaluated for weight loss

Orexigen Therapeutics, Inc. Presents at Jefferies 2014 Global Healthcare Conference, Jun-03-2014 04:00 PM

Orexigen Therapeutics, Inc. Presents at Jefferies 2014 Global Healthcare Conference, Jun-03-2014 04:00 PM. Venue: Grand Hyatt, New York, New York, United States. Speakers: Michael A. Narachi, Chief Executive Officer, President and Director.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OREX:US $5.13 USD -0.16

OREX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for OREX.
View Industry Companies

Industry Analysis


Industry Average

Valuation OREX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 168.6x
Price/Book 28.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 110.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OREXIGEN THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at